Genetic Analysis of TREM2 Variants in Tunisian Patients with Alzheimer’s Disease
Zied Landoulsi, Mouna Ben djebara, Imen Kacem, Youssef Sidhom, Rym Kefi, Sonia Abdelhak, Amina Gargouri-Berrechid, Riadh Gouider

To cite this version:

HAL Id: pasteur-01990539
https://hal-riip.archives-ouvertes.fr/pasteur-01990539
Submitted on 23 Jan 2019

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L’archive ouverte pluridisciplinaire HAL, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d’enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

Distributed under a Creative Commons Attribution 4.0 International License
Genetic Analysis of *TREM2* Variants in Tunisian Patients with Alzheimer's Disease

Zied Landoulsi\(^a\), Mouna Ben Djebara\(^a, b\), Imen Kacem\(^a, b\), Youssef Sidhom\(^a, b\), Rym Kefi\(^c\), Sonia Abdelhak\(^c\), Amina Gargouri-Berrechid\(^a, b\), Riadh Gouider\(^a, b\)

\(^a\)Department of Neurology, UR12SP21, Razi Hospital, Manouba, Tunisia; \(^b\)Faculty of Medicine of Tunis, University of Tunis El Manar, Tunis, Tunisia; \(^c\)Laboratory of Biomedical Genomics and Oncogenetics, Institut Pasteur de Tunis, University of Tunis El Manar, Tunis, Tunisia

Significance of the Study

- Rare variants within exon 2 of the *TREM2* gene increase the risk of Alzheimer's disease in Caucasian populations. This is the first case-control study to assess the association between these variants and the risk of Alzheimer's disease in a North African population. We sequenced exon 2 of the *TREM2* gene in a cohort of Tunisian patients with late-onset Alzheimer’s disease and healthy individuals and identified 5 variants, none of which was associated with the risk of Alzheimer’s disease. Our study does not support a major role for *TREM2* in the pathogenesis of late-onset Alzheimer’s disease in the Tunisian population.

Keywords

*TREM2* gene · Variants · Alzheimer's disease · North-African population · Case-control study

Abstract

**Objective:** Rare variants in the *TREM2* gene have been reported to significantly increase the risk of Alzheimer’s disease in Caucasian populations. Hitherto, this association was not studied in North African populations. In this work, we aimed to study the association between *TREM2* exon 2 variants and the risk of late-onset Alzheimer’s disease (LOAD) in a Tunisian population. **Subjects and Methods:** We sequenced exon 2 of *TREM2* in a Tunisian cohort of 172 LOAD patients and 158 control subjects. We used the Fisher exact test to compare the distribution of allelic frequencies between the two groups. **Results:** We identified 4 previously reported nonsynonymous variants (p.Asp39Glu, p.Arg62His, p.Thr96Lys, and p.Val126Gly) and 1 novel synonymous variant (p.Gln109Gln), none of which was significantly associated with the risk of Alzheimer’s disease. Moreover, the rare *TREM2* variant (p.Arg47His), which was considered to be a risk factor for Alzheimer’s disease in European descent populations, was not detected in our cohort. **Conclusion:** These findings do not support a major role for *TREM2* in the pathogenesis of LOAD in the Tunisian population.

Introduction

*TREM2* gene encodes the triggering receptor expressed on myeloid cells 2, which is highly expressed in microglia of the central nervous system [1] and is involved in regulating the immune system by promoting phagocytosis...
and regulating the inflammatory response. The rare missense mutation p.Arg47His (rs75932628) within TREM2 increases the risk of neurodegenerative disorders such as Parkinson’s disease [2], essential tremor [3], and late-onset Alzheimer’s disease (LOAD). This mutation was identified as a rare risk factor for LOAD in several European descent cohorts with an odds ratio similar to that for apolipoprotein E epsilon 4 (ApoE ε4) [4, 5].

TREM2 variants associated with Alzheimer’s disease (AD) have been screened in various populations worldwide; however, no studies have been carried-out in North African populations. Most of the aforementioned variants were observed in exon 2 of the TREM2 gene. Therefore, the aim of this work was to evaluate the association of TREM2 exon 2 variants with risk of AD in a sample of the Tunisian population.

**Subjects and Methods**

**Subjects**

One hundred seventy-two Tunisian patients with LOAD were recruited from the Neurology Department of Razi Hospital, Manouba, Tunisia. Clinical diagnosis of LOAD was done according to the criteria of the National Institute of Neurological and Communication Disorders and Stroke-Alzheimer’s Disease and Related Disorders Association (NINCDS-ADRDA) [6]. In addition, 158 unrelated control subjects were recruited from different primary care clinics. None of the control group subjects had cognitive impairment or personal or familial history of neurological and psychiatric disorders. Written informed consent was obtained from each individual prior to enrollment in the genetic study. Research protocols were approved by the Medical Ethics Committee of Razi Hospital and conformed to the guidelines of the Declaration of Helsinki.

**ApoE Genotyping and TREM2 Sequencing**

Blood samples were collected from LOAD patients and controls. Genomic DNA was extracted from blood by the salting-out method [7]. ApoE genotyping was performed as previously described [8]. Exon 2 of TREM2 gene was amplified by polymerase chain reaction (PCR) from genomic DNA using two primers: 5’-TGAATGAATTCTCCTCCCCAG-3’ and 5’-CAGCCACTGCCACTCA-3’, under the following reaction conditions: denaturation at 95 °C for 5 min followed by 30 cycles of 95 °C for 30 s, 60 °C for 30 s, and 72 °C for 30 s, and a final cycle of 7-min extension at 72 °C. PCR products were purified and sequenced using the BigDye Terminator Cycle Sequencing Kit v1.1 on a 3,500xl Genetic Analyzer DNA sequencer (Applied Biosystems, Foster City, CA, USA). Sequences were analyzed using the SeqScape software (Applied Biosystems) and compared to the TREM2 GenBank reference sequence (NM_018965).

**In silico Tools**

The impact of TREM2 variations was predicted using SIFT (Sorting Intolerant From Tolerant; http://sift.jcvi.org/www/SIFT_chr_coords_submit.html), PolyPhen-2 (Polymorphism Phenotyping v2; http://genetics.bwh.harvard.edu/pph2/) and PredictSNP2 (http://loschmidt.chemi.muni.cz/predictsnp2/) [9]. Frequencies of variants were reported from exome database (1,000G; http://browser.1000genomes.org/index.html), ExAC (http://exac.broadinstitute.org/), EVS (http://evs.gs.washington.edu/EVS/), and Great Middle East (GME) Variome Project database (http://igm.ucsd.edu/gme/data-browser.php) including 508 samples from North Africa.

**Statistical Analysis**

We used Fisher’s exact test to compare the distribution of allelic frequencies between LOAD patients and control groups. ApoE genotype and sex distributions were compared using the χ² test and mean age was compared using the t test. All analyses were two-tailed and a p value of 0.05 or less was considered statistically significant. Odds ratios and 95% confidence intervals were calculated using SPSS.

**Results**

Demographic characteristics and ApoE genotypes of Tunisian LOAD patients (n = 172) and controls (n = 158) are summarized in Table 1. Both groups had similar sex ratios and similar mean ages. ApoE genotyping showed a
significant difference in genotype distributions between the two groups; as expected, the ApoE ε4 allele was over-represented in LOAD patients compared to the control group (36.9 vs. 16.1%; \( p < 0.05 \)). The ApoE ε2 allele was not detected in patients and controls.

Sequencing of exon 2 of the \( \text{TREM2} \) gene revealed 5 variants in 14 LOAD patients and 1 variant in 5 controls. As shown in Table 2, 4 previously reported nonsynonymous variants (p.Asp39Glu, p.Arg62His, p.Thr96Lys, and p.Val126Gly) and 1 novel synonymous variant (p.Gln109Gln) were observed in patients. The variant p.Thr96Lys was also identified in controls. All variants were present in the heterozygous state and were detected in separate individuals (no individuals carried 2 or more variants). Among the 14 patients carrying the \( \text{TREM2} \) variants, 11 had a positive family history of AD (Table 3).

The frequencies of each variation in the population’s exome sequencing database are detailed in Table 2. No common variants having minor allele frequency (MAF) >5% were found, and 2 variants (p.Val126Gly and p.Asp39Glu) were rare, with MAF <1%. Three variants were predicted to have a probable damaging effect (p.Asp39Glu, p.Thr96Lys, and p.Val126Gly; Table 4). The association analysis of all the identified \( \text{TREM2} \) variants and AD

**Table 2. Variants of \( \text{TREM2} \) after sequencing of exon 2 in LOAD patients and controls**

<table>
<thead>
<tr>
<th>Variant</th>
<th>db SNP ID</th>
<th>Position (GRCh37)</th>
<th>Exonic function</th>
<th>LOAD patients (carriers, MAF)</th>
<th>Controls (carriers, MAF)</th>
<th>( p ) value</th>
<th>OR (95% CI)</th>
<th>Population frequency data</th>
<th>1,000G</th>
<th>gnomAD</th>
<th>EVS</th>
<th>GME</th>
</tr>
</thead>
<tbody>
<tr>
<td>p.Asp39Glu</td>
<td>rs200392967</td>
<td>g.41129275G&gt;C</td>
<td>nonsyn</td>
<td>1 (0.005)</td>
<td>0</td>
<td>1</td>
<td>NA</td>
<td>0.005 0.008 0.007</td>
<td>6.5 e-5 7.6 e-5 0</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>p.Arg62His</td>
<td>rs143332484</td>
<td>g.41129207C&gt;T</td>
<td>nonsyn</td>
<td>2 (0.011)</td>
<td>0</td>
<td>0.49</td>
<td>NA</td>
<td>0.005 0.008 0.007</td>
<td>0.041 0.012 0.039 0</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>p.Thr96Lys</td>
<td>rs2234253</td>
<td>g.41129105G&gt;T</td>
<td>nonsyn</td>
<td>5 (0.029)</td>
<td>6 (0.037)</td>
<td>0.76</td>
<td>1.3 (0.39-4.36)</td>
<td>0.005 0.008 0.007</td>
<td>0.041 0.012 0.039 0</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>p.Gln109Gln</td>
<td>NA</td>
<td>g.41129065C&gt;T</td>
<td>syn</td>
<td>5 (0.029)</td>
<td>0</td>
<td>0.06</td>
<td>NA</td>
<td>0.005 0.008 0.007</td>
<td>8.2 e-6 0 0 0</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>p.Val126Gly</td>
<td>rs121908420</td>
<td>g.41129015A&gt;C</td>
<td>nonsyn</td>
<td>1 (0.005)</td>
<td>0</td>
<td>1</td>
<td>NA</td>
<td>0.005 0.008 0.007</td>
<td>0.041 0.012 0.039 0</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

| LOAD, late-onset Alzheimer’s disease; db SNP, single nucleotide polymorphism database; MAF, minor allele frequency; syn, synonymous; nonsyn, nonsynonymous. |

**Table 3. Characteristics of individuals carrying the \( \text{TREM2} \) variants**

<table>
<thead>
<tr>
<th>Variant</th>
<th>Carrier</th>
<th>Gender</th>
<th>Age at examination/ Age at onset, years</th>
<th>ApoE genotype</th>
<th>Family history of neurodegenerative disease</th>
</tr>
</thead>
<tbody>
<tr>
<td>p.Asp39Glu</td>
<td>patient 1</td>
<td>F</td>
<td>86/82</td>
<td>ε4/ε4</td>
<td>yes</td>
</tr>
<tr>
<td>p.Arg62His</td>
<td>patient 2</td>
<td>M</td>
<td>79/71</td>
<td>ε3/ε3</td>
<td>yes</td>
</tr>
<tr>
<td></td>
<td>patient 3</td>
<td>F</td>
<td>78/71</td>
<td>ε3/ε3</td>
<td>yes</td>
</tr>
<tr>
<td>p.Thr96Lys</td>
<td>patient 4</td>
<td>M</td>
<td>79/66</td>
<td>ε4/ε4</td>
<td>yes</td>
</tr>
<tr>
<td></td>
<td>patient 5</td>
<td>M</td>
<td>69/67</td>
<td>ε3/ε3</td>
<td>yes</td>
</tr>
<tr>
<td></td>
<td>patient 6</td>
<td>F</td>
<td>72/65</td>
<td>ε3/ε4</td>
<td>yes</td>
</tr>
<tr>
<td></td>
<td>patient 7</td>
<td>F</td>
<td>80/75</td>
<td>ε3/ε4</td>
<td>yes</td>
</tr>
<tr>
<td></td>
<td>patient 8</td>
<td>F</td>
<td>89/79</td>
<td>ε3/ε3</td>
<td>yes</td>
</tr>
<tr>
<td></td>
<td>control 1</td>
<td>M</td>
<td>71/–</td>
<td>ε3/ε3</td>
<td>no</td>
</tr>
<tr>
<td></td>
<td>control 2</td>
<td>M</td>
<td>68/–</td>
<td>ε3/ε4</td>
<td>no</td>
</tr>
<tr>
<td></td>
<td>control 3</td>
<td>F</td>
<td>70/–</td>
<td>ε3/ε3</td>
<td>no</td>
</tr>
<tr>
<td></td>
<td>control 4</td>
<td>M</td>
<td>69/–</td>
<td>ε3/ε3</td>
<td>no</td>
</tr>
<tr>
<td></td>
<td>control 5</td>
<td>F</td>
<td>70/–</td>
<td>ε3/ε4</td>
<td>no</td>
</tr>
<tr>
<td>p.Val126Gly</td>
<td>patient 10</td>
<td>F</td>
<td>75/65</td>
<td>ε4/ε4</td>
<td>yes</td>
</tr>
<tr>
<td></td>
<td>patient 11</td>
<td>F</td>
<td>72/67</td>
<td>ε3/ε3</td>
<td>no</td>
</tr>
<tr>
<td></td>
<td>patient 12</td>
<td>F</td>
<td>85/68</td>
<td>ε3/ε4</td>
<td>no</td>
</tr>
<tr>
<td></td>
<td>patient 13</td>
<td>F</td>
<td>77/72</td>
<td>ε3/ε3</td>
<td>no</td>
</tr>
</tbody>
</table>
was not statistically significant (Table 2). Even the rare variants p.Val126Gly and p.Asp39Glu were not significantly associated with AD ($p > 0.05$).

**Discussion**

This is the first investigation into the possible association between TREM2 variants and risk of AD in a North African population. In this study, we sequenced exon 2 of the TREM2 gene in a cohort of Tunisian patients with LOAD and healthy individuals, and identified 5 variants (p.Asp39Glu, p.Arg62His, p.Thr96Lys, p.Gln109Gln, and p.Val126Gly). The p.Arg47His mutation was not found in our cohort. Association analysis revealed that none of the identified variants were associated with AD risk. Therefore, we could not test the interaction of the ApoE ε4 allele with these variants.

A summary of the reported screening studies for TREM2 mutations to date, including AD patients, is presented in Table 5. TREM2 p.Arg62His was previously observed in AD patients and controls in Spanish, Belgian,
and French populations (Table 5), and did not show a nominally significant association with AD. However, a previous case-control study of large European American descent cohorts showed that in addition to p.Arg47His [10], p.Arg62His is a risk factor for AD. The variant rs2234253 (p.Thr96Lys), detected in Belgian, French, and Japanese populations (Table 5), was not shown to enhance AD risk. In our study, p.Thr96Lys was the unique variant detected in controls and LOAD patients with equivalent MAF. According to public exome databases, this variant was more common in African populations (MAF = 14.5%, 1,000G) than other populations, but was not present in North African populations of the GME (Table 2).

Two rare variants predicted to be deleterious, p.Asp39Glu and p.Val126Gly, were identified in our study. The p.Asp39Glu was previously reported in 2 AD patients at the heterozygous state [11], while homozygous p.Val126Gly was reported in 2 patients with Nasu-Hakola disease [12]. Among the 5 variants, variant Gln109Gln was not found in any of the exome databases. However, this variant is synonymous and does not change the amino acid sequence of TREM2 protein.

The previously reported rare variant rs75932628 (p.Arg47His), identified to be a risk factor for AD in Caucasian populations (Table 5), was not found in our cohort. Our findings are in agreement with published reports of African American, Iranian, and East Asian populations (Table 5) which showed that the p.Arg47His mutation could not be linked to an increased risk of AD. In our study, the lack of association of the p.Arg47His variant may be due to its very low MAF in the Tunisian population. In the GME database, this genetic polymorphism had a global MAF of 0.15 and 0.1% in North African populations. Moreover, this variant is considered to be a risk factor according to the ethnicity of the population. AD risk in the Tunisian population may be influenced by genetic and/or environmental factors which might reduce the effect of this variant. However, the limitation of our work is the small cohort size, which could explain the lack of statistical significance.

**Conclusion**

This study is the first to explore the possibility of an association of TREM2 with the risk of AD in North Africa, particularly in Tunisia. This population seems to be closer to the African American or East Asian populations than to the European ones regarding the AD risk factor p.Arg47His. We hypothesize that variations in exon 2 of TREM2 may not play a major role in the pathogenesis of LOAD in the Tunisian population. However, further studies on larger cohorts of North African populations are needed to confirm this hypothesis.

**Acknowledgements**

We are grateful to all the patients and their family members for participating in this study. This research was supported by grants from the Tunisian Ministry of Higher Education and Scientific Research and the Tunisian Ministry of Health.

**Disclosure Statement**

The authors declare that they have no conflicts of interest.

---

### References


